• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Hikma Pharma unveils $300 million expansion

Hikma Pharma unveils $300 million expansion

April 2, 2012
CenterWatch Staff

Hikma Pharmaceuticals, a generic drug and injectables specialist based in Amman, Jordan, plans to spend nearly $300 million in 2012 on acquisitions and expansion initiatives in the Middle East and North Africa, according to Hikma’s CFO, Khalid Nabilsi.

"In terms of acquisitions, we can do $150 million to $200 million this year through debt. We are also planning to invest $90 million on expansions at the group level financed by the internal cash generation," Nabilsi said. "Our focus in 2012 is going to be on product acquisitions that complement our businesses.”

Hikma, which sells branded drugs and has an injectable drugs businesses in Europe and the U.S., expects to benefit from people demanding a better quality of life as a result of the Arab Spring.

"The new regimes and governments believe more in social services; they are committed to investing billions on healthcare and education," Nabilsi said.

Healthcare spending per capita in the Mena region is below $100, compared with $900 in the U.S. and Europe, explained Nabilsi. The sector is witnessing 12% growth in the region, compared with 2% in Europe.

Hikma generates almost 50% of its revenue from the Mena region, operating in 17 countries in Mena, with plants Morocco, Egypt, Tunisia and Sudan. Hikma also has plants in Europe and the U.S.

Nabilsi said he was expecting a strong performance in 2012, with revenue growth expected to be about 20%, driven by opportunities in Mena and the global injectable drugs market. The company is eyeing expansion in Iraq, Turkey and North Africa, Nabilsi commenting that Turkey was a big market while South Africa was an "interesting opportunity."

Hikma gave a positive outlook for 2012 growth last month despite a dip in profits for 2011, reflecting a weaker performance from its generics drugs units and costs from higher wages and currency fluctuations in the Mena region.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing